Negative Evidence Matters in Interpretable Histology Image ClassificationDownload PDF

Published: 28 Feb 2022, Last Modified: 29 Apr 2024MIDL 2022Readers: Everyone
Keywords: Weakly supervised learning, deep learning, histology images, interpretability, positive evidence, negative evidence
TL;DR: we use positve/negative evidence to segment ROI in histology images using only global image class as supervision.
Abstract: Using only global image-class labels, weakly-supervised learning methods, such as class activation mapping, allow training CNNs to jointly classify an image, and locate regions of interest associated with the predicted class. However, without any guidance at the pixel level, such methods may yield inaccurate regions. This problem is known to be more challenging with histology images than with natural ones, since objects are less salient, structures have more variations, and foreground and background regions have stronger similarities. Therefore, computer vision methods for visual interpretation of CNNs may not directly apply. In this paper, a simple yet efficient method based on a composite loss is proposed to learn information from the fully negative samples (i.e., samples without positive regions), and thereby reduce false positives/negatives. Our new loss function contains two complementary terms: the first exploits positive evidence collected from the CNN classifier, while the second leverages the fully negative samples from training data. In particular, a pre-trained CNN is equipped with a decoder that allows refining the regions of interest. The CNN is exploited to collect both positive and negative evidence at the pixel level to train the decoder. Our method called NEGEV benefits from the fully negative samples that naturally occur in the data, without any additional supervision signals beyond image-class labels. Extensive experiments show that our proposed method can substantial outperform related state-of-art methods on GlaS (public benchmark for colon cancer), and Camelyon16 (patch-based benchmark for breast cancer using three different backbones). Our results highlight the benefits of using both positive and negative evidence, the first obtained from a classifier, and the other naturally available in datasets.
Registration: I acknowledge that publication of this at MIDL and in the proceedings requires at least one of the authors to register and present the work during the conference.
Authorship: I confirm that I am the author of this work and that it has not been submitted to another publication before.
Paper Type: methodological development
Primary Subject Area: Segmentation
Secondary Subject Area: Interpretability and Explainable AI
Confidentiality And Author Instructions: I read the call for papers and author instructions. I acknowledge that exceeding the page limit and/or altering the latex template can result in desk rejection.
Community Implementations: [![CatalyzeX](/images/catalyzex_icon.svg) 1 code implementation](
6 Replies